
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical spray containing anthralin, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No finished anthralin product of any kind is listed; the directory holds only bulk ingredient records for it.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Prescribers order this preparation for patients with plaque psoriasis, and sometimes alopecia areata. Manufactured anthralin 1% cream is FDA-approved for psoriasis; this preparation is a different form.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Anthralin is a topical antipsoriatic agent used on the skin and scalp that a pharmacy may compound when a prescriber orders it.
Anthralin, also called dithranol, is a synthetic topical agent used for psoriasis. Its exact mechanism is not fully understood, but studies show it slows the overgrowth of skin cells and calms inflammation; the slowing of skin cell growth appears to come from both inhibition of DNA synthesis and its strong reducing properties. The anthralin products currently listed on DailyMed, Zithranol shampoo, labeled for scalp psoriasis in people 12 and older, and Zithranol-RR cream, labeled for stable plaque psoriasis, are marketed as prescription drugs without FDA approval. StatPearls lists topical anthralin among options for alopecia areata that has not responded to other treatment, which is not an FDA-approved indication. A prescriber might order anthralin compounded in a strength, vehicle or combination that is not available. Compounded preparations are not FDA-approved and require a prescription.
Anthralin labels carry no boxed warning. Do not use it if you are allergic to anthralin or any ingredient, and the cream label says not to use it on acute or actively inflamed psoriasis. Keep it away from the eyes and mucous membranes, take care on the face and skin folds, and wash your hands after use. Irritation, burning and redness are common. It temporarily stains skin, hair and nails and can permanently stain fabrics, plastics and tubs. Stop and contact your prescriber if irritation becomes severe, an allergic reaction occurs, or lesions spread. The labels state anthralin does not inhibit liver enzymes, so drug interactions are thought to be unlikely. The labels advise use in pregnancy only if clearly needed. LactMed notes it has not been studied in breastfeeding, has suspected mutagenic properties, and should not contact the baby's skin. Talk to your prescriber or pharmacist about side effects.
Anthralin (1,8-dihydroxy-9-anthrone) has antiproliferative and anti-inflammatory effects on psoriatic and normal skin; label-described mechanisms include inhibition of DNA synthesis, strong reducing properties, induction of lipid peroxidation and reduction of endothelial adhesion molecules. StatPearls describes inhibition of T-cell activation and promotion of keratinocyte differentiation, and a 2020 eLife study reported reduced epidermal hyperproliferation and neutrophil chemoattractants and inhibition of the IL-36 inflammatory loop. Unlike retinoids and PUVA, anthralin does not inhibit hepatic microsomal enzymes. Irritancy depends on strength, contact time and individual tolerance, which is the basis for short-contact regimens; StatPearls describes contact times up to 2 hours with improvement over 8 to 12 weeks. In the eLife study, erythema did not correlate with clinical response. Labeled products, both marketed without FDA approval: Zithranol shampoo for scalp psoriasis and Zithranol-RR cream for stable plaque psoriasis, the latter contraindicated in acute or actively inflamed eruptions. Anthralin has shown tumor-promoting properties on mouse skin, though the label reports no human carcinogenic effects. Use for alopecia areata is not an FDA-approved indication. Dosing and contact time are per prescriber. Monitor for irritation, sensitization and lesion spread.
Wash your hands. Shake the bottle if your label says to. Hold the nozzle a short distance from the skin and spray the number of times on your label, then let it dry. Do not spray near the eyes, nose or mouth, and do not breathe in the mist. Avoid open flame if the spray contains alcohol. Wash your hands afterward.
Topical sprays are aqueous or alcohol based. Under USP <795>, a preserved aqueous spray usually carries a beyond-use date of up to 35 days; an unpreserved one 14 days refrigerated; a nonaqueous spray may carry up to 180 days. Keep the bottle closed, away from heat and flame, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)